Sensyne Health appoints Charles Swingland as Non-Executive Chairman

Sensyne Health appoints Charles Swingland as Non-Executive Chairman

September 23, 2019

Oxford, UK; Sensyne Health plc (LSE:SENS), the British clinical AI technology company, is pleased to announce that Charles Swingland has been appointed Non-Executive Chairman of the Board, effective immediately. Mr Swingland had previously served as Non-Executive Director and Interim Chairman.

-ENDS-

For more information please contact:

Sensyne Health
(www.sensynehealth.com)
+44 (0) 330 058 1845


Lord (Paul) Drayson, Chief Executive Officer
Lorimer Headley, Chief Financial Officer

Peel Hunt  LLP (Nominated Adviser and Broker)
+ 44 (0) 20 7418 8900


Dr Christopher Golden
James Steel
Oliver Jackson

Consilium  Strategic Communications
+44 (0) 20 3709 5700


Mary-Jane Elliott
Sukaina Virji
Melissa Gardiner
sensynehealth@consilium-comms.com

About Sensyne Health

Sensyne Health plc is a healthcare technology company that creates value from accelerating the discovery and development of new medicines and improving patient care through the analysis of real-world evidence from large databases of anonymised patient data in collaboration with NHS Trusts. These anonymised patient data are ethically sourced in that any analysis of anonymised patient data (and hence the Company’s access to it) must be pre-approved for each programme on a case-by-case basis by the relevant NHS Trusts. This is to ensure that the purpose of the anonymisation and the proposed analysis are subject to appropriate ethical oversight and information governance, including conformance with NHS principles, UK data protection law and applicable regulatory guidance. Sensyne Health is an early signatory to the Department of Health and Social Care’s ‘Initial Code of Conduct for data-driven health and care technology.

Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).